Antitubercular Agents | UTIs | Antiviral Agents | Unit 3 Medicinal Chemistry 6th Semester
This is a comprehensive lecture covering Unit 3 of Medicinal Chemistry for 6th semester, focusing on three major drug classes: antitubercular agents (including first and second-line drugs like Isoniazid and Ethambutol), urinary tract anti-infective agents (quinolones and miscellaneous drugs), and antiviral agents (both antiretroviral and non-retroviral drugs).
Summary
The lecture begins with an extensive discussion of antitubercular agents, explaining tuberculosis as a chronic infectious disease caused by Mycobacterium tuberculosis. The instructor describes how TB can be classified based on site of action (pulmonary vs extrapulmonary) and active state (active vs latent TB). He emphasizes the critical importance of patient compliance with treatment, explaining how first-line drugs (Isoniazid, Rifampin, Pyrazinamide, and Ethambutol) work as a four-drug combination therapy for 9-12 months, and how non-compliance can lead to multi-drug resistant TB requiring second-line drugs. The lecture covers detailed mechanisms of action for synthetic antitubercular drugs and antitubercular antibiotics, including synthesis pathways for key drugs like Isoniazid and para-aminosalicylic acid.
The second major section covers urinary tract infections and their treatment agents. The instructor explains UTIs as bacterial infections affecting any part of the urinary system (kidneys, ureters, bladder, urethra), with E. coli being the most common causative organism. He discusses four types of UTIs: cystitis, urethritis, pyelonephritis, and ureteritis, along with their symptoms. The treatment focuses on quinolones, particularly explaining their mechanism through DNA replication interference by blocking topoisomerase enzymes. A detailed structure-activity relationship analysis of quinolones is provided, followed by synthesis of ciprofloxacin and discussion of miscellaneous drugs like nitrofurantoin.
The final section addresses antiviral agents, distinguishing between antiretroviral agents (targeting retroviruses like HIV that convert RNA to DNA via reverse transcription) and non-retroviral agents (targeting other viruses). For antiretrovirals, he covers NRTIs (nucleoside reverse transcriptase inhibitors), NNRTIs (non-nucleoside reverse transcriptase inhibitors), and protease inhibitors, explaining their mechanisms in disrupting HIV replication. Non-retroviral agents include anti-herpes drugs like acyclovir, anti-influenza drugs that prevent viral uncoating, and anti-hepatitis C drugs like ribavirin that work through multiple mechanisms including viral RNA polymerase interference and lethal mutagenesis.
Key Insights
- The instructor emphasizes that tuberculosis treatment requires strict patient compliance with four-drug combination therapy for 9-12 months, and even missing 5-6 days can lead to bacterial resistance and treatment failure
- He explains that first-line TB drugs work very effectively when taken consistently, achieving nearly 100% cure rates, but second-line drugs have lower success rates and are used only when first-line treatment fails due to resistance
- The lecturer describes quinolones' mechanism as targeting bacterial DNA replication by inhibiting topoisomerase enzymes, specifically DNA gyrase and topoisomerase IV, which are essential for DNA unwinding during replication
- He clarifies that retroviruses are unique because they convert RNA to DNA using reverse transcriptase enzyme, unlike normal cellular processes where DNA creates RNA, making them targets for specific antiretroviral drugs
- The instructor explains that ribavirin works against hepatitis C virus through four different mechanisms: interfering with viral RNA polymerase, inhibiting IMP dehydrogenase, causing lethal mutagenesis, and enhancing host immune response
Topics
Full transcript available for MurmurCast members
Sign Up to Access